GSA Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.96M | Buy |
+3,831
| New | +$2.93M | 0.18% | 66 |
|
|
2025
Q4 | – | Sell |
-3,440
| Closed | -$1.93M | – | 2014 |
|
|
2025
Q3 | $1.93M | Buy |
3,440
+1,358
| +65% | +$768K | 0.16% | 90 |
|
|
2025
Q2 | $1.09M | Sell |
2,082
-326
| -14% | -$182K | 0.08% | 404 |
|
|
2025
Q1 | $1.53M | Buy |
2,408
+432
| +22% | +$297K | 0.14% | 159 |
|
|
2024
Q4 | $1.41M | Buy |
1,976
+1,343
| +212% | +$1.13M | 0.1% | 217 |
|
|
2024
Q3 | $665K | Buy |
+633
| New | +$704K | 0.05% | 726 |
|
|
2024
Q1 | – | Sell |
-459
| Closed | -$403K | – | 1906 |
|
|
2023
Q4 | $403K | Buy |
+459
| New | +$378K | 0.03% | 938 |
|
|
2023
Q1 | – | Sell |
-359
| Closed | -$259K | – | 1856 |
|
|
2022
Q4 | $259K | Sell |
359
-521
| -59% | -$384K | 0.03% | 1032 |
|
|
2022
Q3 | $606K | Buy |
880
+350
| +66% | +$220K | 0.08% | 436 |
|
|
2022
Q2 | $313K | Buy |
+530
| New | +$345K | 0.05% | 794 |
|
|
2021
Q4 | – | Sell |
-2,228
| Closed | -$1.35M | – | 1731 |
|
|
2021
Q3 | $1.35M | Buy |
2,228
+1,850
| +489% | +$1.15M | 0.14% | 171 |
|
|
2021
Q2 | $211K | Buy |
+378
| New | +$192K | 0.02% | 1160 |
|
|
2020
Q2 | – | Sell |
-422
| Closed | -$206K | – | 1031 |
|
|
2020
Q1 | $206K | Sell |
422
-578
| -58% | -$238K | 0.05% | 737 |
|
|
2019
Q4 | $375K | Sell |
1,000
-2,308
| -70% | -$777K | 0.04% | 854 |
|
|
2019
Q3 | $918K | Buy |
3,308
+1,665
| +101% | +$493K | 0.12% | 202 |
|
|
2019
Q2 | $514K | Sell |
1,643
-2,782
| -63% | -$926K | 0.06% | 655 |
|
|
2019
Q1 | $1.82M | Buy |
4,425
+1,725
| +64% | +$710K | 0.18% | 82 |
|
|
2018
Q4 | $1.01M | Buy |
+2,700
| New | +$988K | 0.12% | 220 |
|
|
2017
Q3 | – | Sell |
-549
| Closed | -$270K | – | 1850 |
|
|
2017
Q2 | $270K | Sell |
549
-592
| -52% | -$259K | 0.02% | 1337 |
|
|
2017
Q1 | $442K | Sell |
1,141
-1,341
| -54% | -$497K | 0.02% | 1169 |
|
|
2016
Q4 | $911K | Sell |
2,482
-3,216
| -56% | -$1.22M | 0.05% | 612 |
|
|
2016
Q3 | $2.29M | Sell |
5,698
-10,341
| -64% | -$4.15M | 0.12% | 194 |
|
|
2016
Q2 | $5.6M | Sell |
16,039
-4,899
| -23% | -$1.89M | 0.31% | 9 |
|
|
2016
Q1 | $7.55M | Buy |
20,938
+12,551
| +150% | +$5.17M | 0.48% | 2 |
|
|
2015
Q4 | $4.55M | Sell |
8,387
-9,438
| -53% | -$5.11M | 0.22% | 36 |
|
|
2015
Q3 | $8.29M | Buy |
17,825
+8,666
| +95% | +$4.65M | 0.41% | 17 |
|
|
2015
Q2 | $4.67M | Buy |
9,159
+2,187
| +31% | +$1.07M | 0.18% | 59 |
|
|
2015
Q1 | $3.15M | Buy |
6,972
+1,572
| +29% | +$666K | 0.13% | 139 |
|
|
2014
Q4 | $2.21M | Buy |
+5,400
| New | +$2.12M | 0.15% | 121 |
|
|
2014
Q3 | – | Sell |
-53,930
| Closed | -$15.2M | – | 1897 |
|
|
2014
Q2 | $15.2M | Buy |
53,930
+50,003
| +1,273% | +$14.8M | 0.69% | 3 |
|
|
2014
Q1 | $1.18M | Sell |
3,927
-12,325
| -76% | -$3.8M | 0.08% | 260 |
|
|
2013
Q4 | $4.47M | Buy |
+16,252
| New | +$4.67M | 0.35% | 22 |
|
|
2013
Q3 | – | Sell |
-20,851
| Closed | -$4.69M | – | 1643 |
|
|
2013
Q2 | $4.69M | Buy |
+20,851
| New | +$4.86M | 0.56% | 9 |
|
Other funds holding REGN
VCM
N
GSA Capital Partners's REGN Position: Q1 2026 in Review
GSA Capital Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 3,831 shares worth $2.96M. The stake represents 0.18% of the portfolio and ranks #66 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in REGN as recently as Q3 2025.
GSA Capital Partners first reported a position in REGN in Q2 2013 and has held it in 33 quarters since. The position peaked at $15.2M in Q2 2014. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- GSA Capital Partners held 3,831 shares of Regeneron Pharmaceuticals worth $2.96M as of Q1 2026.
- Regeneron Pharmaceuticals was a new GSA Capital Partners position in Q1 2026.
- Regeneron Pharmaceuticals made up 0.18% of GSA Capital Partners's portfolio in Q1 2026, its #66 holding.
- GSA Capital Partners first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
- GSA Capital Partners's Regeneron Pharmaceuticals position peaked at $15.2M in Q2 2014.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.